Palo Alto Networks' (PANW) $25 billion purchase of CyberArk (CYBR) and Thoma Bravo's planned $12.3 billion acquisition of Dayforce are among the deals likely to close in the new year. "Thoma Bravo is ...
Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced. Aficamten is an allosteric and reversible inhibitor of ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Copyright © 2025 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback